HI-Bi leverages human genetic and immunological insights to deliver targeted therapies to patients with severe immune-mediated diseases.
Funding Date | Share Class | Amount Raised | Price per Share | Post-Money Valuation | Key Investors | |
---|---|---|---|---|---|---|
10/20/2022 | Series A-1 | $2.2MM | $xx.xx | $97.78MM | Tom Brown, Jonas Schneider, Drew Houston, Arash Ferdowsi, Astera Institute | |
Price per Share
$xx.xx
Shares Outstanding
4,142,280
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
8.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
N/A
Key Investors
Tom Brown, Jonas Schneider, Drew Houston, Arash Ferdowsi, Astera Institute
|
||||||
10/20/2022 | Series A | $20MM | $xx.xx | $97.78MM | Tom Brown, Jonas Schneider, Drew Houston, Arash Ferdowsi, Astera Institute | |
Price per Share
$xx.xx
Shares Outstanding
28,276,940
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
8.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
N/A
Key Investors
Tom Brown, Jonas Schneider, Drew Houston, Arash Ferdowsi, Astera Institute
|